Emory Unit Laboratory: Persons Under Investigation

Loading...

From the course by Emory University

Ebola Virus Disease: An Evolving Epidemic

125 ratings

Explore Related Videos

At Coursera, you will find the best lectures in the world. Here are some of our personalized recommendations for you

Emory University

Ebola Virus Disease: An Evolving Epidemic

125 ratings

Learn about the evolving Ebola epidemic and its various aspects including disease prevention, management and treatment, response to the epidemic, ethical considerations, and the post-Ebola global health landscape.

From the lesson

Laboratory Issues

Upon completion of this module, learners will be able to: Discuss clinical laboratory considerations for Ebola Virus Disease.Differentiate between persons under investigation and persons with confirmed EVD. Identify where and how EVD laboratory testing is performed. Recognize the safety concerns surrounding the disposal of specimens and human remains. Explore the immune response to EVD and discuss the implications for future therapeutics and vaccines.

Emory Unit Laboratory: Persons Under Investigation 6:21

Emory Unit Laboratory: Persons with Confirmed EVD 15:16

Meet the Instructors

Dabney P. Evans, PhD, MPH
Assistant Professor
Hubert Department of Global Health. Rollins School of Public Health. Director, Center for Humanitarian Emergencies.
Carlos del Rio, MD
Chair
Department of Global Health at the Rollins School of Public Health

My name is Charlie Hill.

I am the Director of the Molecular Diagnostics Laboratory for

Emory University Hospital and was the Medical Director for

our Serious Communicable Diseases Unit Laboratory during our activation for

Ebola patients.

going to be talking about the laboratory response for Ebola.

So in general.

A dedicated laboratory for patients under investigation, or

known positive Ebola patients isn't necessary.

But, we have to find a way to adequately protect our staff from blood and

body fluid exposures, and we have to provide clinically relevant,

quality test results for our patients.

There are now guidelines in appropriate collection and

transport of samples for suspected Ebola patients, and

these have been provided by the CDC and also the World Health Organization.

Patients under investigation fall under three possible categories,

low risk, intermediate risk, and high risk is designated by the CDC and WHO.

Because it may take up to three days,

after symptoms appear, before virus reaches detectable levels.

So, what happens is, we collect one or more blood, ETEA tubes.

That's a standard blood tube,

that's a four milliliter draw that we test for virus.

Now, what we do while we're waiting on that viral testing to be completed.

Depends on the individual laboratory because if the adequate resources

are there to do additional testing in a protected way, that can be done as well.

The risk assessment, while it falls under three categories,

the laboratory generally considers only two.

Those that require testing for Ebola, and those that don't.

The patient doesn't require testing for Ebola.

Those samples tend to just go to the main laboratory for regular evaluation.

The samples are collected for those patients that do need testing by personnel

trained in the appropriate personal protective equipment, and

transported in a safe fashion to the laboratory.

That transport requires that the specimen be in a durable, leak proof container.

In a way that it is unlikely to provide risk to any of

the people handling the transporting container.

One very important aspect of this,

because Ebola does fall under a category of a potential agent of bioterrorism,

is that we have to monitor disposition of all of the specimens

until we know whether the specimens are positive for Ebola virus or not.

There are a number of test available from various vendors for Ebola testing.

The current paradigm is that you should test for Ebola nucleic acid, Ebola RNA.

And these Ebola RNA tests have been given

emergency use authorization under the FDA for the United States.

There are a few that only available in designated laboratories.

There's a Department of Defense reverse transcription PCR.

CDC has two different reverse-transcription PCRs, and

there is a commercial entity, BioFire Defense,

that provides the FilmArray diagnostic for Ebola.

In CLIA certified laboratories, clinical laboratories that are certified for

moderate or high complexity testing,.

BioFire Defense provides the FilmArray Biothreart-E test which is available

commercially.

There are two other test available under emergency use authorization for

high complexity laboratories only from two other commercial vendors.

Emery's approach to persons under investigation is the patients determined

to be at risk by the emergency department.

The emergency physician then notifies the serious communicable diseases unit

physician on call, who does an additional risk evaluation and

determines if testing is necessary for Ebola.

That physician notifies our serious communicable diseases unit

laboratory director on call, who then activates the SCDU lab.

The lab director on call then notifies the testing personnel

who will come into the serious serious communicable diseases unit laboratory,

which is separate from the main hospital lab.

The screening sample is drawn at the bedside where the patient currently is

sequestered, and transported to the SCDU laboratory.

Screening test results are available in one to one and a half hours after receipt.

And the basic labs may also be performed more of as a convenience during that time

period because the laboratory technologist is waiting on that result to.

To complete.

For specimen transport within the healthcare facility, we utilize a durable

leak proof container, usually, a plastic box with locking handles.

And we may use the same or similar, containers that are typically used for

shipping category A pathogens.

Those are available commercially.

We do not use the pneumatic tube system that we would normally transport patient

specimens through because of the risk of a tube rupturing, and

contaminating the pneumatic tube system.

Most importantly we have to minimize the risk of breakage of the tubes or

spilling of the samples.

Between facilities espe-, even for patients under investigation.

Any time a sample that might have a category A pathogen is going to travel

on a public conveyance or on roads within the United States requires adherence to

the hazardous materials regulations of the U.S. Department of Transportation.

There are shipping containers that are designed to minimize the risk of spills.

Even in the event of an automobile or

airplane accident, these, commercial products can be shipped through a number

of shippers within the United States, carriers such as Federal Express,

because they do have the appropriate certifications to transport them.

Once the specimen is received and testing for Ebola is completed.

It is then necessary to change the status of the patient

depending on the particular result that was generated.

So, for positive patients,

those individuals would be admitted to our serious communicable diseases unit, and

further care would be provided in that very controlled environment.

With regard to negative patients,

typically what will happen is that those patients are continued to be monitored

for, monitored for symptomatology for an additional number of days.

Up to 21 days from the initial symptoms.

So that we can verify that they did not in fact have the Ebola virus disease.

Explore our Catalog

Join for free and get personalized recommendations, updates and offers.

Coursera provides universal access to the world’s best education, partnering with top universities and organizations to offer courses online.

© 2019 Coursera Inc. All rights reserved.

Download on the App Store

Get it on Google Play